Laura Godfrey Hendon

Ms. Laura Godfrey Hendon

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Sabrina SuckielSabrina Suckiel
Sabrina Suckiel
JOJulianne O'Daniel
Julianne O'Daniel
KDKatherine E. Donohue
Katherine E. Donohue
KGKatie M. Gallagher
Katie M. Gallagher
MGMarian J. Gilmore
Marian J. Gilmore
LALaura M. Amendola
Laura M. Amendola
Genomic sequencing results need to be effectively communicated across all populations and practice settings. Projects in the Clinical Sequencing Evidence-Generating Research (CSER) consortium enroll diverse racial/ethnic and medically underserved participants across various clinical contexts. This article explores a set of CSER results disclosure cases to expand the evidence base on experiences returning genomic results. Case details were collected using a structured set of questions. We identified common themes in the case set, and assessed challenges and strategies in achieving six relevant results disclosure objectives. CSER-affiliated patient/community stakeholder impressions of the findings were solicited via video conference calls. Seventeen cases across six CSER projects were included. Case themes sorted into four categories: (1) factors influencing participant understanding, (2) participant emotional response, (3) disease burden, and (4) logistical challenges. Challenges meeting results disclosure objectives included a lack of dialogue, health literacy level, unexpected findings, and complex concepts. Strategies were consistent with traditional genetic counseling practice, but also highlighted approaches being evaluated in CSER projects. Patient/community stakeholders supported the identified themes and provided additional suggestions to improve patient understanding and engagement. These experiences add valuable insights into adapting genomic results disclosure practices to best serve all patient populations.

Verified
Journal Article
Open access
PDF file
ALAmy A. Lemke
Amy A. Lemke
MTMichelle Thompson
Michelle Thompson
EGEmily C. Gimpel
Emily C. Gimpel
KMKatelyn C. McNamara
Katelyn C. McNamara
CRCarla A. Rich
Carla A. Rich
KBKyle B. Brothers
Kyle B. Brothers
Background: It is critical to understand the wide-ranging clinical and non-clinical effects of genome sequencing (GS) for parents in the NICU context. We assessed parents’ experiences with GS as a first-line diagnostic tool for infants with suspected genetic conditions in the NICU. Methods: Parents of newborns (N = 62) suspected of having a genetic condition were recruited across five hospitals in the southeast United States as part of the SouthSeq study. Semi-structured interviews (N = 78) were conducted after parents received their child’s sequencing result (positive, negative, or variants of unknown significance). Thematic analysis was performed on all interviews. Results: Key themes included that (1) GS in infancy is important for reproductive decision making, preparing for the child’s future care, ending the diagnostic odyssey, and sharing results with care providers; (2) the timing of disclosure was acceptable for most parents, although many reported the NICU environment was overwhelming; and (3) parents deny that receiving GS results during infancy exacerbated parent–infant bonding, and reported variable impact on their feelings of guilt. Conclusion: Parents reported that GS during the neonatal period was useful because it provided a “backbone” for their child’s care. Parents did not consistently endorse negative impacts like interference with parent–infant bonding.

23 July 2021 in Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
EBEmily Boothe
Emily Boothe
BWBrayden West
Brayden West
LHLaura Godfrey Hendon
Laura Godfrey Hendon
JKJulie D. Kaplan
Julie D. Kaplan
BKBrian Kirmse
Brian Kirmse

1 May 2023 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
AMAhmed Zaki Moustafa
Ahmed Zaki Moustafa
SASarah Araji
Sarah Araji
NCNatalie Clericuzio
Natalie Clericuzio
DFDanielle Frieson
Danielle Frieson
LHLaura Godfrey Hendon
Laura Godfrey Hendon
INTRODUCTION: Triploidy is a chromosomal abnormality that occurs in 1–3% of all conceptions and often results in early spontaneous miscarriage. It is exceedingly rare for a triploid fetus to survive to birth. Neonates usually die within hours to days after delivery. After the Dobbs v Jackson Women's Health Organization ruling in July 2022, access to abortion is becoming increasingly limited, and therefore providers should consider the adverse maternal health outcomes that can be associated with triploidy. METHODS: In this case series, we describe three cases of confirmed fetal triploidy that we encountered in our center within 1 year (2021–2022). All three cases were referred to us after House Bill 1259 was passed on July 1, 2020, in Mississippi banning termination of pregnancy based on race, sex, or genetic abnormality. RESULTS: Our first case is a 21-year-old patient referred at 19 weeks 2 days for abnormal second-trimester serum screen. Ultrasound showed an enlarged multicystic placenta and multiple fetal anomalies. Amniocentesis showed a 69,XXY karyotype. Patient was managed expectantly. At 21 week 5 days, patient was diagnosed with superimposed preeclampsia with severe features. Patient underwent medical termination of pregnancy. The second case is a 25-year-old referred at 30 weeks 0 days for concerns of fetal anomalies. Ultrasound confirmed multiple fetal anomalies. Amniocentesis showed a 69,XXY karyotype. Patient was diagnosed with preeclampsia and pulmonary edema and was delivered at 30 weeks 1 day. The neonate passed away at 22 days of life. Our third case is a 20-year-old referred at 24 weeks 0 days for abnormal aneuploidy screening. Ultrasound showed a major cardiac defect and severe fetal growth restriction. Amniocentesis showed a 69,XXY karyotype. Patient was managed expectantly. At 29 weeks 0 days, intrauterine fetal demise was diagnosed. Patient was diagnosed with peripartum depression. CONCLUSION: Women with pregnancies affected by fetal triploidy are at risk of developing preeclampsia. Restricting access to abortion will lead to increased maternal morbidity and mortality rates.

1 April 2021 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
LALaura Amendola
Laura Amendola
Sabrina SuckielSabrina Suckiel
Sabrina Suckiel
JOJulianne O’dAniel
Julianne O’dAniel
KDKatherine Donohue
Katherine Donohue
KGKatie Gallagher
Katie Gallagher
TYTiffany Yip
Tiffany Yip

31 July 2026 in American Journal of Perinatology Reports
Verified
Journal Article
Open access
LHLaura Godfrey Hendon
Laura Godfrey Hendon